Radiotherapy (2500 rad) for testicular leukemia

Local control and subsequent clinical events: A southwest oncology group study

Margaret P. Sullivan, Carlos A. Perez, Jay Herson, Mario Silva‐Sousa, Vita Land, Paul G. Dyment, Rafael Chan, Alberto G. Ayala

Research output: Contribution to journalArticle

Abstract

The effectiveness of radiotherapy, 2500 rad over two weeks, in treating leukemic infiltrates of the testicles was studied in 38 boys who met the requirements for tissue confirmation of testicular involvement and examination of the bone marrow. The study group was heterogeneous with respect to specific histology and prior therapy. Complete regression of testicular infiltrates was confirmed by repeat biopsy examinations of 32 of 33 patients undergoing the procedure. The single treatment failure occurred in a boy with acute myelogenous leukemia. In all other patients, local disease control following radiotherapy persisted throughout the remainder of the clinical course. Three of 5 children, however, showed evidence of reseeding of the testicle as a part of the relapse process at post‐mortem examination. Statistical analysis of data from the 35 patients with acute lymphocytic leukemia showed the subsequent course of the disease with respect to next relapse, involving either bone marrow (BM) or the central nervous system (CNS), to be dependent on the acute leukemia prognostic group, as determined by age and peripheral white blood cell count (WBC) at the time of diagnosis, and timing of extramedullary disease (EMD). Patients with poor prognosis at the time of diagnosis and EMD afterward had a 3.8 times greater risk of a subsequent BM or CNS relapse than did patients with good or average prognosis and no EMD at any time (P = 0.07). Of the candidate prognostic factors examined with respect to survival, only the number of prior BM relapses was of statistical significance (P = 0.044). Children with two or more prior BM relapses had the worst prognosis for survival from testicular relapse, with a death risk of 3.6 times greater per unit of time than that of children with no or one prior BM relapse. Protective BM and CNS rescue therapy was recommended for those otherwise in complete remission (CR) at the time of testicular relapse. The median times to next relapse for patients receiving both BM and CNS rescue therapy and for patients given CNS rescue only were 42+ and seven weeks, respectively (P = 0.09). The type of rescue received did not appear to affect survival time following testicular CR. Cancer 46:508–515, 1980.

Original languageEnglish (US)
Pages (from-to)508-515
Number of pages8
JournalCancer
Volume46
Issue number3
DOIs
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Leukemia
Radiotherapy
Recurrence
Bone Marrow
Central Nervous System
Survival
Testis
Bone Marrow Examination
Statistical Data Interpretation
Treatment Failure
Leukocyte Count
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Autopsy
Histology
Therapeutics
Biopsy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Radiotherapy (2500 rad) for testicular leukemia : Local control and subsequent clinical events: A southwest oncology group study. / Sullivan, Margaret P.; Perez, Carlos A.; Herson, Jay; Silva‐Sousa, Mario; Land, Vita; Dyment, Paul G.; Chan, Rafael; Ayala, Alberto G.

In: Cancer, Vol. 46, No. 3, 01.01.1980, p. 508-515.

Research output: Contribution to journalArticle

Sullivan, Margaret P. ; Perez, Carlos A. ; Herson, Jay ; Silva‐Sousa, Mario ; Land, Vita ; Dyment, Paul G. ; Chan, Rafael ; Ayala, Alberto G. / Radiotherapy (2500 rad) for testicular leukemia : Local control and subsequent clinical events: A southwest oncology group study. In: Cancer. 1980 ; Vol. 46, No. 3. pp. 508-515.
@article{085bbeeee84441a8aaf2b4e6feb2da39,
title = "Radiotherapy (2500 rad) for testicular leukemia: Local control and subsequent clinical events: A southwest oncology group study",
abstract = "The effectiveness of radiotherapy, 2500 rad over two weeks, in treating leukemic infiltrates of the testicles was studied in 38 boys who met the requirements for tissue confirmation of testicular involvement and examination of the bone marrow. The study group was heterogeneous with respect to specific histology and prior therapy. Complete regression of testicular infiltrates was confirmed by repeat biopsy examinations of 32 of 33 patients undergoing the procedure. The single treatment failure occurred in a boy with acute myelogenous leukemia. In all other patients, local disease control following radiotherapy persisted throughout the remainder of the clinical course. Three of 5 children, however, showed evidence of reseeding of the testicle as a part of the relapse process at post‐mortem examination. Statistical analysis of data from the 35 patients with acute lymphocytic leukemia showed the subsequent course of the disease with respect to next relapse, involving either bone marrow (BM) or the central nervous system (CNS), to be dependent on the acute leukemia prognostic group, as determined by age and peripheral white blood cell count (WBC) at the time of diagnosis, and timing of extramedullary disease (EMD). Patients with poor prognosis at the time of diagnosis and EMD afterward had a 3.8 times greater risk of a subsequent BM or CNS relapse than did patients with good or average prognosis and no EMD at any time (P = 0.07). Of the candidate prognostic factors examined with respect to survival, only the number of prior BM relapses was of statistical significance (P = 0.044). Children with two or more prior BM relapses had the worst prognosis for survival from testicular relapse, with a death risk of 3.6 times greater per unit of time than that of children with no or one prior BM relapse. Protective BM and CNS rescue therapy was recommended for those otherwise in complete remission (CR) at the time of testicular relapse. The median times to next relapse for patients receiving both BM and CNS rescue therapy and for patients given CNS rescue only were 42+ and seven weeks, respectively (P = 0.09). The type of rescue received did not appear to affect survival time following testicular CR. Cancer 46:508–515, 1980.",
author = "Sullivan, {Margaret P.} and Perez, {Carlos A.} and Jay Herson and Mario Silva‐Sousa and Vita Land and Dyment, {Paul G.} and Rafael Chan and Ayala, {Alberto G.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19800801)46:3<508::AID-CNCR2820460315>3.0.CO;2-I",
language = "English (US)",
volume = "46",
pages = "508--515",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Radiotherapy (2500 rad) for testicular leukemia

T2 - Local control and subsequent clinical events: A southwest oncology group study

AU - Sullivan, Margaret P.

AU - Perez, Carlos A.

AU - Herson, Jay

AU - Silva‐Sousa, Mario

AU - Land, Vita

AU - Dyment, Paul G.

AU - Chan, Rafael

AU - Ayala, Alberto G.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - The effectiveness of radiotherapy, 2500 rad over two weeks, in treating leukemic infiltrates of the testicles was studied in 38 boys who met the requirements for tissue confirmation of testicular involvement and examination of the bone marrow. The study group was heterogeneous with respect to specific histology and prior therapy. Complete regression of testicular infiltrates was confirmed by repeat biopsy examinations of 32 of 33 patients undergoing the procedure. The single treatment failure occurred in a boy with acute myelogenous leukemia. In all other patients, local disease control following radiotherapy persisted throughout the remainder of the clinical course. Three of 5 children, however, showed evidence of reseeding of the testicle as a part of the relapse process at post‐mortem examination. Statistical analysis of data from the 35 patients with acute lymphocytic leukemia showed the subsequent course of the disease with respect to next relapse, involving either bone marrow (BM) or the central nervous system (CNS), to be dependent on the acute leukemia prognostic group, as determined by age and peripheral white blood cell count (WBC) at the time of diagnosis, and timing of extramedullary disease (EMD). Patients with poor prognosis at the time of diagnosis and EMD afterward had a 3.8 times greater risk of a subsequent BM or CNS relapse than did patients with good or average prognosis and no EMD at any time (P = 0.07). Of the candidate prognostic factors examined with respect to survival, only the number of prior BM relapses was of statistical significance (P = 0.044). Children with two or more prior BM relapses had the worst prognosis for survival from testicular relapse, with a death risk of 3.6 times greater per unit of time than that of children with no or one prior BM relapse. Protective BM and CNS rescue therapy was recommended for those otherwise in complete remission (CR) at the time of testicular relapse. The median times to next relapse for patients receiving both BM and CNS rescue therapy and for patients given CNS rescue only were 42+ and seven weeks, respectively (P = 0.09). The type of rescue received did not appear to affect survival time following testicular CR. Cancer 46:508–515, 1980.

AB - The effectiveness of radiotherapy, 2500 rad over two weeks, in treating leukemic infiltrates of the testicles was studied in 38 boys who met the requirements for tissue confirmation of testicular involvement and examination of the bone marrow. The study group was heterogeneous with respect to specific histology and prior therapy. Complete regression of testicular infiltrates was confirmed by repeat biopsy examinations of 32 of 33 patients undergoing the procedure. The single treatment failure occurred in a boy with acute myelogenous leukemia. In all other patients, local disease control following radiotherapy persisted throughout the remainder of the clinical course. Three of 5 children, however, showed evidence of reseeding of the testicle as a part of the relapse process at post‐mortem examination. Statistical analysis of data from the 35 patients with acute lymphocytic leukemia showed the subsequent course of the disease with respect to next relapse, involving either bone marrow (BM) or the central nervous system (CNS), to be dependent on the acute leukemia prognostic group, as determined by age and peripheral white blood cell count (WBC) at the time of diagnosis, and timing of extramedullary disease (EMD). Patients with poor prognosis at the time of diagnosis and EMD afterward had a 3.8 times greater risk of a subsequent BM or CNS relapse than did patients with good or average prognosis and no EMD at any time (P = 0.07). Of the candidate prognostic factors examined with respect to survival, only the number of prior BM relapses was of statistical significance (P = 0.044). Children with two or more prior BM relapses had the worst prognosis for survival from testicular relapse, with a death risk of 3.6 times greater per unit of time than that of children with no or one prior BM relapse. Protective BM and CNS rescue therapy was recommended for those otherwise in complete remission (CR) at the time of testicular relapse. The median times to next relapse for patients receiving both BM and CNS rescue therapy and for patients given CNS rescue only were 42+ and seven weeks, respectively (P = 0.09). The type of rescue received did not appear to affect survival time following testicular CR. Cancer 46:508–515, 1980.

UR - http://www.scopus.com/inward/record.url?scp=0018932935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018932935&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19800801)46:3<508::AID-CNCR2820460315>3.0.CO;2-I

DO - 10.1002/1097-0142(19800801)46:3<508::AID-CNCR2820460315>3.0.CO;2-I

M3 - Article

VL - 46

SP - 508

EP - 515

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -